In vitro assessment of cytochrome P450 inhibition and induction potential of felotaxel (SHR110008)
- PMID: 22397757
- DOI: 10.1016/j.biopha.2012.01.001
In vitro assessment of cytochrome P450 inhibition and induction potential of felotaxel (SHR110008)
Abstract
The purpose of this study was to assess the potential inhibitory and inductive effects of felotaxel on cytochrome P450 isozymes in vitro. The inhibitory effects of felotaxel on various CYP isozymes were determined in human liver microsomes. In addition, the ability of felotaxel to induce CYP enzymes in cultured human hepatocytes was evaluated. Results showed that felotaxel did not inhibit CYP1A2-, CYP2C9-, CYP2C19-, CYP2E1-, CYP2D6-, CYP2B6-, CYP2C8-, and mediated activities in human liver microsomes up to a concentration of 100 μM, while the inhibition (<30% inhibition) of CYP3A4 activities was observed at 100 μM felotaxel. In vitro felotaxel did not induce CYP1A2, CYP2C19, or CYP3A4/5 activities in cultured human hepatocytes. In present study, felotaxel has been identified as a potent inhibitor of metabolic activity of CYP3A4. Therefore, clinically relevant pharmacokinetic drug-drug interactions are likely to occur between felotaxel and co-administered substrates of these CYP3A4 isozymes. These findings provided some useful information for safe and effective use of felotaxel in clinical practice.
Copyright © 2012 Elsevier Masson SAS. All rights reserved.
Similar articles
-
In vitro assessment of cytochrome P450 inhibition and induction potential of tanespimycin and its major metabolite, 17-amino-17-demethoxygeldanamycin.Cancer Chemother Pharmacol. 2012 Jan;69(1):51-6. doi: 10.1007/s00280-011-1672-2. Epub 2011 May 19. Cancer Chemother Pharmacol. 2012. PMID: 21594721
-
Lenalidomide: in vitro evaluation of the metabolism and assessment of cytochrome P450 inhibition and induction.Cancer Chemother Pharmacol. 2009 May;63(6):1171-5. doi: 10.1007/s00280-008-0867-7. Epub 2008 Nov 23. Cancer Chemother Pharmacol. 2009. PMID: 19030860
-
In vitro assessment of cytochrome P450 inhibition and induction potential of azacitidine.Cancer Chemother Pharmacol. 2010 Apr;65(5):995-1000. doi: 10.1007/s00280-010-1245-9. Epub 2010 Jan 30. Cancer Chemother Pharmacol. 2010. PMID: 20119716 Free PMC article.
-
The effects of gender, age, ethnicity, and liver cirrhosis on cytochrome P450 enzyme activity in human liver microsomes and inducibility in cultured human hepatocytes.Toxicol Appl Pharmacol. 2004 Sep 15;199(3):193-209. doi: 10.1016/j.taap.2004.01.010. Toxicol Appl Pharmacol. 2004. PMID: 15364537 Review.
-
System-dependent outcomes during the evaluation of drug candidates as inhibitors of cytochrome P450 (CYP) and uridine diphosphate glucuronosyltransferase (UGT) enzymes: human hepatocytes versus liver microsomes versus recombinant enzymes.Drug Metab Pharmacokinet. 2010;25(1):16-27. doi: 10.2133/dmpk.25.16. Drug Metab Pharmacokinet. 2010. PMID: 20208386 Review.
Cited by
-
A Gastric Cancer Peptide GX1-Modified Nano-Lipid Carriers Encapsulating Paclitaxel: Design and Evaluation of Anti-Tumor Activity.Drug Des Devel Ther. 2020 Jun 12;14:2355-2370. doi: 10.2147/DDDT.S233023. eCollection 2020. Drug Des Devel Ther. 2020. PMID: 32606603 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources